Objectives: Low back pain (LBP) is the second most frequently diagnosed pain condition in the United States, and although a majority of individuals have resolution of pain during the acute period, an estimated 40% of individuals will experience persistent pain. Given the heterogenous nature of LBP, this study sought to describe and compare somatosensory and molecular (gene expression) profiles between individuals with acute LBP and healthy nopain controls.
L ow back pain (LBP) is a musculoskeletal symptom defined as discomfort in the region between the thoracolumbar and lumbosacral junctions and is considered to be "acute" up to the first 6 weeks after onset. 1 It is the second most frequently diagnosed pain condition in the United States, and although a majority of individuals have resolution of pain during the acute period, an estimated 40% of individuals will experience persistent LBP, lasting for >12 weeks. [2] [3] [4] [5] [6] Given the heterogenous and multidimensional nature of LBP, researchers have focused on psychosocial and environmental risk factors as a means of identifying individuals at risk for persistent LBP. [7] [8] [9] [10] [11] Abundant evidence demonstrates that these factors contribute to pain; however, interventions designed to reduce psychosocial and environmental risk factors have only been marginally successful in decreasing the incidence of longterm pain and disability. [12] [13] [14] [15] Less attention has been focused on characterizing the somatosensory alterations associated with acute LBP, which may provide a deeper understanding of the biologically relevant pain mechanisms involved in this condition as well as the transition from acute to persistent LBP.
One method of characterizing the pain experience is through quantitative sensory testing (QST), which was primarily introduced to detect and differentiate between neuropathic syndromes, but also represents a standardized and comprehensive tool for somatosensory testing. The advantages of QST are that it is noninvasive and measures different modalities of pain (mechanical, heat, and cold) with reproducibly controlled protocols. 16 Whereas there have been several studies demonstrating increased peripheral and central sensitivity in individuals with chronic LBP, 17, 18 few studies have used comprehensive QST protocols to assess for somatosensory alterations during the acute phase. A study that compared only pressure pain threshold (PPT) in acute and chronic LBP participants found that the chronic group had localized and generalized pressure hyperalgesia, which was not present in the acute group. 19 LeResche et al 20 used PPTs, cold pressor pain ratings, conditioned pain modulation, and mechanical temporal summation in patients with acute LBP to assess whether test responses predicted clinically significant back pain 4 months later. Of the psychophysical tests used, lower PPTs significantly predicted back pain at 4 months but the associations were no longer significant after controlling for participant age and sex. More recently, Hu¨bsher et al 21 used thermal thresholds and tolerance as well as temporal summation to evaluate differences between individuals with acute LBP, chronic LBP, and healthy (no-pain) controls. They found that chronic LBP participants had significantly more sensitive cold pain threshold in the painful area of the back as well as a remote site compared with no-pain controls; however, participants with acute LBP did not show elevated pain sensitivity in response to the selected tests. Whereas these studies suggest efficient pain modulation in individuals with acute LBP, 22 to our knowledge, there have been no studies to systematically evaluate peripheral and central sensory alterations using QST during an acute episode of LBP.
Although a precise structural etiology of persistent LBP is rarely present, recent studies document functional alterations that reflect peripheral and possibly central nervous system sensitization. 23, 24 Peripheral sensitization may be triggered by inflammatory processes resulting from tissue or nerve injury and manifests as increased sensitivity to experimental pain restricted to the site of injury. In contrast, central sensitization can manifest as allodynia, hyperalgesia, and/or enhanced temporal summation in noninjured regions of the body. Enhanced sensitivity to experimental pain may be a trait characteristic, possibly conferred through genetic polymorphisms that influence pain signaling. 25 However, accumulating evidence indicates that sensitivity to pain can also develop over time in response to modifications in the expression of genes that encode pain signaling molecules and their receptors, particularly genes associated with neurotrophins, [26] [27] [28] [29] inflammatory mediators, 30 and catecholamines. 31 Altered levels of these pain signaling molecules and their receptors are thought to be important for the early steps of nervous system sensitization. Given that levels of gene expression associated with enhanced pain sensitivity are potentially modifiable, 32 further elucidation of the differences in somatosensory function and gene expression at the onset of LBP, during the acute phase, may provide foundational knowledge to evaluate and guide the development of predictive markers and preventative interventions to reduce the incidence of persistent LBP.
Therefore, we sought to describe and compare somatosensory responses to experimental pain and gene expression data between individuals with acute LBP and healthy (no-pain) controls. Using a previously established protocol, 16 we comprehensively compared QST parameters between no-pain control participants and those with acute LBP. As this study was exploratory we did not select specific parameters to compare. However, our hypothesis was that there would be significant differences in somatosensory function and gene expression profiles between the acute LBP group and the no-pain control group.
MATERIALS AND METHODS

Participants
Men and women between the ages of 18 and 50 years of age diagnosed with an acute nonspecific LBP episode and able to read and write in English were invited to participate from primary health care clinics through advertisements. An acute nonspecific LBP episode was defined as pain anywhere in the region of the low back bound superiorly by the thoracolumbar junction and inferiorly by the lumbosacral junction, which had been present for >24 hours but <4 weeks' duration and was preceded by at least 1 pain-free month. 33 This age range was selected to provide a more homogenous sample in terms of general health, work status, and contributing factors of persistent LBP. Recruitment took place at an urban university health system in the mid-Atlantic region after approval from the Institution Review Board. All participants provided written consent before study participation.
Patients were excluded for the following conditions: (1) pain at another site or associated with a painful condition (eg, degenerative disk disease, herniated lumbar disk, fibromyalgia, neuropathy, rheumatoid arthritis, sciatica);
(2) previous spinal surgery; (3) presence of neurological deficits; (4) history of comorbidities that affect sensorimotor function (eg, multiple sclerosis, spinal cord injury, diabetes); (5) pregnant or within 3 months' postpartum; (6) taking opioid, antidepressants, or anticonvulsant medication; and, (7) history of psychological disorders (major depression, bipolar disorder, schizophrenia) because of a possible associations with biological markers. [34] [35] [36] Eligibility for the healthy, no-pain control (NPC) group included men and women (1) between 18 and 50 years of age; (2) could read and write in English; (3) with no known medical, psychological problems or prescribed medication; (4) not pregnant or breastfeeding; and, (5) no recent history of pain at any other location.
We estimated the sample size based on a previous study that compared LBP patients with healthy controls and reported the effect size of several QST parameters (with Cohen d ranging from 0.80 to 1.12). 18 Using the more conservative effect size of 0.8 to achieve a power of 80% at probability level of 0.05, the minimum sample size using a 1-tailed hypothesis was estimated to be 21 per group. 37, 38 Because of the exploratory nature of the study, it was deemed most appropriate to increase the size to 31 per group to ensure adequate power to detect significant differences between groups.
Procedures
After obtaining informed consent, participants were scheduled to undergo baseline data collection as soon as possible but no longer than 1 week from the time of consent. Data collection took place in a private research suite to complete questions about age, sex, socioeconomic status, educational attainment, lifestyle behaviors (smoking, exercise), comorbidities, and past episodes of LBP. Following completion of the questionnaires, participants underwent venipuncture for collection of blood samples and QST. The sequence of data collection was followed for all participants.
QST
QST was used to evaluate responses to experimental pain and uses standardized stimuli to test both nociceptive and non-nociceptive systems. 16, 38 QST was performed in the lumbar region (at the location of pain for the acute LBP group) and on the dominant forearm (remote area). A standardized protocol of administration, including examination room conditions and instructions provided for the participant, were strictly followed. Participants were given a practice run on the nondominant forearm to verify the participant's understanding of the protocol.
Mechanical pain threshold and sensitivity were measured with a standard set of von Frey hairs (Optihair 2 -Set; Marstock Nervtest, Germany) that exert forces between 0.25 and 512 mN with a rounded tip that is 0.5 mm in diameter. The final threshold is calculated as the geometric mean of 5 series of ascending and descending stimuli intensities. Wind-up ratio (WUR) was determined from this series with the mean pain rating of trains divided by the mean pain rating to a single stimuli. Dynamic mechanical allodynia (ALL) was tested using a standardized brush applied 5 times with a single stroke; the pain rating to each stroke was recorded.
Thermal and pressure testing was performed using the Medoc Pathway System (Ramat Yishai, Israel). The Medoc thermode, with contact area of 7.84 cm 2 , was placed in contact with the participant's skin in the area to be tested. The Medoc software guided the examiner through a series of thermal testing procedures in the following order: cold detection threshold, warm detection threshold, cold pain threshold, and heat pain threshold. The mean threshold temperature of 3 consecutive measurements were calculated and used for analysis. All thresholds were obtained with ramped stimuli (11C/s) that were terminated when the participant pressed a button attached to the Medoc device. Cut-off temperatures were 0 and 501C with a baseline temperature of 321C. For PPT, the examiner used an algometer (range from 50 to 600 kPa) attached to the Medoc Pathways system to increase the pressure at a steady rate (30 kPa/s) until the participant indicated first pain sensation by pressing the button. The PPT was determined by repeating the procedure at the same site until either: (1) 2 values were recorded within 20 kPa of one another or (2) 3 trials were administered. In either case, the mean of the two closest values were recorded as the threshold estimate. During the testing, the computer screen was positioned so that the participant was not able to watch temperature and pressure fluctuations.
Gene Expression Profiles
Whole blood was collected by venipuncture into one 5-mL EDTA vacutainer and one 10-mL cell preparation tube with sodium citrate, labeled with a unique study identification label, and transported directly to the laboratory for processing. RNA isolation was performed using the PAXgene total RNA isolation system (Qiagen, Valencia, CA) according to the manufacturer's protocol and was reverse transcribed using iScript cDNA synthesis kit (Invitrogen, Valencia, CA). The mRNA expression of 84 genes involved in the transduction, maintenance, and modulation of pain was determined (Neuropathic & Inflammatory RT2 Profiler PCR Array; Sabio Sciences, Valencia, CA; BioRad, Hercules, CA) using qPCR performed on the BioRad CFX96. After an initial incubation step, 35 cycles (951C for 15 s and 1 min at 601C) of PCR were performed. Expression levels were quantified using the DDC t method which normalizes data of the genes of interest to b-actin (controls are included in array). The BioRadCFX software was used to determine optimal baseline and threshold settings of the assay C t values.
Statistical Analysis
Normality of the data was tested using the Kolmogorov-Smirnov test. The Student t tests were used to test for group differences in demographic and QST variables that were normally distributed, whereas the Kruskal-Wallis test followed by Bonferroni-Holm adjusted Mann-Whitney U test for post hoc analyses were used for variables that were not normally distributed. Categorical variables were compared using the w 2 tests. Post hoc analyses were conducted as necessary to account for multiple testing. For gene expression analyses, each LBP participant was randomly matched to NPC participants by age within 3 years and sex. Five male LBP participants who could not be matched based on the criteria were matched with the remaining participants in the same group with the closest age. Missing C q values were imputed by 35, a maximum cycle of PCR performed. For each housekeeping gene (HKG) included in the assay (ACTB, B2M, GAPDH, HPRT1, and RPLP0), the GAPDH was the most stable and suitable HKG used for normalization of the C q values as it exhibited the lowest variance and highest abundance. Results are based on normalization using the GAPDH and the 3 most stable HKGs (GAPDH, ACTB, and B2M). For each of the 86 non-HKGs considered "genes of interest" (GOI), the DC q value was calculated as DC q = C q,GOI ÀC q,GAPDH . Thereafter, for each participant, the relative fold change in expression was calculated as 2 ÀDðDCqÞ , where D(DC q ) = DC q , LBP ÀDC q , Normal , or DC q , LBPvisit5 ÀDC q , LBPvisit1 . For each comparison, a linear model was fit for each gene with sample group as the independent variable. Empirical Bayes method was applied to obtain robust estimators. 39 Benjamini and Hochberg's method was used to control the false discovery rate. 40 The moderated unpaired and paired t statistics were computed for the 2 sample comparisons. Nonparametric tests were applied as appropriate. The differentially expressed genes were defined with false discovery rate <5%.
RESULTS
Study Participant Characteristics
Demographic and clinical information of the participants is shown in Table 1 . Of note, there were more African American participants in the acute LBP group compared with the NPC group (P < 0.01). There were more participants in the acute LBP group earning an annual income <$60,000 compared with the control group (P < 0.01) and more participants were working full-time or part-time in the control group compared with the acute LBP group (P = 0.01). In addition, more participants in the control group had started college or were currently pursuing advanced education compared with the acute LBP group (P < 0.01). Although there were no significant differences in exercise frequency, a significantly higher number of participants in the acute LBP group were current smokers and had common comorbidities such as hypertension compared with the control group (P < 0.01 and P < 0.05, respectively). As expected, the acute LBP group had significantly more prior episodes of LBP compared with the control group (P < 0.01) but none reported a prior episode lasting >3 months in the previous 6 months.
Patients With Acute LBP Have Lower Pain Threshold and Higher Pain Scores Compared With No-Pain Controls
pain was elicited at a higher temperature in the acute LBP group. The PPT was significantly lower only in the back area of the acute LBP group compared with the control group (P < 0.01), meaning that less pressure stimulus was required to elicit pain. Mechanical sensitivity and the WUR were significantly higher in both the remote and back area in the acute LBP group compared with the control group (P < 0.01 for both), meaning that the acute LBP group reported higher pain scores to a set mechanical stimulus. Finally, pain scores were significantly elevated in response to a standard brush applied to the painful back region in the acute LBP compared with controls (P < 0.01) suggesting mechanical allodynia ( Table 2) .
Patients With Acute LBP Have Differential Gene Expression Compared With No-Pain Controls
When GAPDH was used for normalization, 10 genes were differentially expressed in the acute LBP group as compared with the control group (3 upregulated and 7 dysregulated). The 3 upregulated genes were CCL2, PNOC, and CNR2. The 7 dysregulated genes were GCH1, CSF1, CALCA, PTGES, GDNF, KCNQ2and HTR2A. The mean D(DC q ) and fold change expression values can be found in Table 3 . Results of gene expression when using ATCB, B2M, and GAPDH as reference genes in normalization are also provided in Table 4 . Upregulation of PNOC was significantly associated with mechanical sensitivity of the back region (Spearman r = 0.359, P = 0.047). Dysregulation of CALCA and GDNF were significantly associated with cold pain threshold at the remote site (r = 0.541, P = 0.002 and r = 0.431, P = 0.015, respectively), whereas CSF1 was associated with WUR of the painful back region (r = 0.368, P = 0.050).
DISCUSSION
The primary aim of this study was to describe and compare somatosensory/pain sensitivity measures and gene expression data between individuals with acute LBP and healthy (no-pain) controls NPCs. This study indicates a unique profile of somatosensory alterations and differential gene expression present at the initial episode of acute LBP and is the first, to our knowledge, to report these differences in comparison with NPCs. Significantly, we found that acute LBP participants showed selective pain sensitivity enhancement and differential gene expression profiles compared with NPCs. The acute LBP group exhibited increased pain sensitivity to cold stimuli, mechanical stimuli, including mechanical temporal summation at both the painful back area and remote location. Along with mechanical allodynia of the painful back region, these findings suggest a mechanism of enhanced central nervous system excitability in participants with acute LBP. In addition, deep tissue-specific peripheral sensitization was suggested in the acute LBP group due to significant differences in PPT of the painful back area, but not the remote body site. Although previous studies have reported sensory alterations among participants with chronic LBP, this study is the first to report indications of selective peripheral and central sensitization in participants with acute LBP compared with NPCs. For instance, O'Neill and colleagues showed that chronic but not acute LBP patients have reduced PPT. 19, 41 Similarly, Hu¨bsher et al 21 reported significantly lower cold pain threshold in the painful area of the back as well as a remote site in chronic LBP compared with no-pain controls. The authors note only a nonsignificant trend of cold sensitivity in the acute LBP compared with chronic LBP group; however, the small sample size of the acute LBP group (n = 20) may have influenced the ability to detect significant differences. Collectively, the findings from the present study complement and extend the results from previous investigations measuring somatosensory changes in participants with acute and chronic LBP. 20,21 A common finding among these studies is that participants with acute and chronic LBP display more sensitive pain thresholds at the lumbar site, albeit the QST endpoints that were altered in acute versus chronic LBP are different. For example, in a chronic LBP sample, Puta et al 18 found increased cold and warm detection thresholds, which were unaltered in our acute LBP participants. The differences in these endpoints could be due to the stage at which LBP was tested suggesting that the presentation of pain changes over time. Alternately, it could point to the heterogenous nature of the condition, thus making pain management modalities complex.
In addition to differences in somatosensory function, we found 10 genes that were differentially expressed (3 upregulated and 7 dysregulated) in the acute LBP group compared with NPCs. Of the upregulated genes, chemokine (C-C motif) ligand 2 (CCL2) upregulation has previously been shown in the oral surgery model of tissue injury and acute pain, with upregulation associated with pain intensity at 3 hours postsurgery along with increased levels of proinflammatory cytokines. 42 Prepronociceptin (PNOC), the precursor of nociceptin, appears to induce upregulation of cytokines and interleukin-10 decreases the expression of PNOC. 43 Upregulation of PNOC was associated with mechanical sensitivity of the painful back region in the acute LBP group, suggesting a role in contributing to peripheral sensitization. We also found upregulated cannabinoid type-2 (CB2) receptor (CNR2) gene expression consistent with the findings in a postmortem study and vast preclinical literature that the CB2 receptor and endocannabinoid system play an important role in modulating pain sensitivity. 44, 45 As increased expression of the CNR2 gene has been associated with reduced pain sensitivity, it remains unclear why higher expression levels were found in the acute LBP group. However, in the presence of multiple dysregulated genes GCH1, CSF1, TRPV1, CALCA, PTGES, GDNF, and KCNQ2 found in participants with acute LBP, there may be interactions that contribute to the sensory alterations observed. Noting that expression does not imply transcription of proteins and due to the design of the study we cannot assume causality. Differential gene expression may be directly related to activation of nociceptive pathways as has been described in skin, muscle, and dorsal root ganglion after plantar incision in a rat model of acute pain. 46 In that study, few genes changed in the DRG; however, there were several dysregulated neurotrophin genes in the skin and muscle. Further research to characterize pain-associated somatosensory changes in the context of altered mRNA expression levels may provide insight on the molecular underpinnings of maladaptive chronic pain. For instance, in patients with complex regional pain syndrome, genome-wide expression profiling of whole blood revealed differential expression of 80 genes involved in signal transduction, cell structure and motility, and immunity. 47 Given the small sample size, it is beyond the scope of this study to predict definitive genetic markers of the somatosensory changes that occur in acute LBP. Nonetheless, these preliminary findings provide some evidence of potential candidate genetic markers that may influence pain signaling and inflammatory processes during the acute stage. This study has several limitations. First, the study enrolled volunteers and blinding of the examiner to group status was not possible due to the requirement of assessing the region of pain in the acute LBP group. Second, the sample size is small to detect generalizable differences in gene expression and further research in this area should be conducted to confirm the upregulated and dysregulated genes identified. Third, our sample did not match on all demographic characteristics such as race and education; however, the demographics of the acute LBP group were consistent with previous literature. 1, 2 A prospective blinded study with matched controls based on age, sex, race, socioeconomic level, educational attainment, and smoking status may assist in clarifying the study findings. In addition, because many participants in the acute LBP group had previous episodes of LBP, one could argue that this was a heterogenous sample of participants with acute (first-episode and recurrent) LBP. However, contrary to traditional thought that recurrent pain leads to persistent sensitization of peripheral and central pain processing, Slade et al 48 found that participants with intermittent painful temporomandibular joint disorder did not exhibit increased sensitization to pressure stimuli once the pain resolved. Whether the same phenomenon occurs during the continuum of intermittent/recurrent LBP, in which flare-ups frequently occur, remains to be systematically evaluated.
This study is the first to characterize the manifestations of nervous system sensitization through rigorous quantitative pain sensitivity testing at the onset of an acute episode of nonspecific LBP with results compared with nopain controls. In addition, this study is among the first to examine gene expression profiles in whole blood of participants with acute LBP. We have systematically identified a unique profile of somatosensory parameters and differential gene expression in an acute LBP sample compared with NPCs. Future studies will examine these parameters in a longitudinal cohort to determine whether there are specific indicators of somatosensory function and gene expression that contribute to persistent LBP.
